biote Corp. (BTMD)

NASDAQ: BTMD · IEX Real-Time Price · USD
4.03
+0.26 (6.90%)
Jul 1, 2022 4:00 PM EDT - Market closed

Company Description

biote Corp. operates in medical practice-building business within the hormone optimization space.

The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements.

It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

biote Corp.
Country United States
Founded 2012
Industry Medical Care Facilities
Sector Health Care
Employees 4

Contact Details

Address:
1875 West Walnut Hill Lane
Irving, TX 75038
United States
Phone 844-604-1246

Stock Details

Ticker Symbol BTMD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 1819253
ISIN Number US0906831039
SIC Code 2833

Key Executives

Name Position
Marc D. Beer Executive Chairman
Teresa S. Weber Chief Executive Officer and Director
Robbin Gibbins Chief Financial Officer
Cary M. Paulette Chief Revenue Officer
Joe Butler Chief Information Officer
Mary Elizabeth Conlon Vice President of Business Development and General Counsel
Richard Kevin Key Chief Digital Officer and Head of Marketing
Jennifer Schimmel Director of Human Resources and Talent
Jade Beutler Head of Nutraceuticals
Dr. Ross W. McQuivey M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Jun 28, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Jun 22, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Jun 17, 2022 S-1 General form for registration of securities under the Securities Act of 1933
Jun 9, 2022 8-K Current report
Jun 2, 2022 8-K Current report
May 31, 2022 4 Statement of changes in beneficial ownership of securities
May 31, 2022 4 Statement of changes in beneficial ownership of securities
May 31, 2022 4 Statement of changes in beneficial ownership of securities
May 31, 2022 4 Statement of changes in beneficial ownership of securities
May 31, 2022 4 Statement of changes in beneficial ownership of securities